【摘要】 目的观察男性肝硬化患者骨质疏松的发生率并评价阿仑膦酸钠的近期疗效。方法127例男性肝硬化患者接受骨密度检测,并对其中筛检出的骨质疏松患者进行阿仑膦酸钠治疗,疗程6个月,对比观察治疗前后骨密度的改变和骨转化指标。结果男性肝硬化患者的骨质疏松发生率为(57.48%),显著高于正常对照组(P<0.01),且与肝功能分级相关;阿仑膦酸钠治疗6个月后,患者腰椎,股骨颈,Ward′s三角区骨密度值显著上升(P均<0.05)。治疗后血清钙升高,血清磷、尿DPD/Cr值下降。结论男性肝硬化患者存在较高的骨质疏松的发生率,阿仑膦酸钠治疗男性肝硬化并发骨质疏松的近期疗效显著。更多还原

【Abstract】 Objective To Investigate the incidence of osteoporosis and the therapeutic effect of alendronate in male liver cirrhosis patients.Methods Bone mineral density (BMD) was measured in 127 male patients with liver cirrhosis. The osteoporotic patients were treated with alendronate. The changes in bone mineral density and blood biochemistries before and after 6 months treatment were compared.Results The incidence of osteoporosis in male liver cirrhosis patients (57.48%) was higher than those in normal control group (P<0.01).After 6 months treatment, the BMD of the lumbar vertebraes, femur neck and the Ward′s triangle increased(P<0.05). The serum calcium level increased and serum DPD/Cr decreased after treatment.Conclusion Incidence of osteoporosis in male liver cirrhosis patients was higher than thar in the normal group. Alondronate is an effective drug for the male patients with osteoporosis.更多还原